The company reported strong fiscal Q4 results with revenue jumping 19% year-over-year and issued better-than-expected guidance for fiscal 2027, projecting 9-10% constant-currency revenue growth and operating margin expansion. While DA Davidson lowered its price target from $375 to $325, it maintained a Buy rating, citing solid performance. Analysts highlight the company as an AI beneficiary, with a real-world partnership to develop next-generation prosthetics showcasing its AI-driven engineering capabilities beyond traditional markets.